How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Transarterial Chemoembolization (TACE) Market
- By Procedure Type: Conventional TACE (cTACE), Drug-Eluting Beads TACE (DEB-TACE), Balloon-Occluded TACE (B-TACE)
- By Indication: Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer, Cholangiocarcinoma, Neuroendocrine Tumors
- By Embolic Agent: Drug-Eluting Beads, Lipiodol, Gelatin Sponge Particles, Polyvinyl Alcohol (PVA) Particles
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
- By Product Type: Embolic Materials, Chemotherapeutic Drugs, Delivery Systems (Catheters and Microcatheters)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Conventional TACE (cTACE) leads By Procedure Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.173 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.181 →
Full report · locked preview
Everything inside the Transarterial Chemoembolization (TACE) Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Procedure Type 3
Indication 4
Embolic Agent 4
End User 3
Product Type 3
Companies profiled
Boston Scientific Corporation
Terumo Corporation
Cook Medical (a division of Cook Group)
Medtronic plc
Becton
Dickinson and Company (BD)
Siemens Healthineers
Philips Healthcare
Stryker Corporation
C.R. Bard (now part of BD)
Merit Medical Systems Inc.
AngioDynamics Inc.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cook Medical (a division of Cook Group)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Stryker Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →C.R. Bard (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Merit Medical Systems Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →AngioDynamics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Penumbra Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Johnson & Johnson (Ethicon)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →GE Healthcare
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Biocompatibles UK Ltd (a BTG International group company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,471M by 2033 · 7.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Conventional TACE (cTACE)72.6
- Drug-Eluting Beads TACE (DEB-TACE)13.2
- Balloon-Occluded TACE (B-TACE)14.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$279.2M → $467.8M · 6.7%
Europe$194.6M → $315.8M · 6.2%
Asia Pacific$177.7M → $337.6M · 8.4%
Latin America$110.0M → $204.7M · 8.1%
Middle East and Africa$84.6M → $143.1M · 6.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.112026
7.132027
7.142028
7.152029
7.172030
7.182031
7.182032
7.202033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Boston Scientific Corporation16.9
- Terumo Corporation20.8
- Cook Medical (a division of Cook Group)6.8
- Medtronic plc9.8
- Becton8.3
- Dickinson and Company (BD)9.4
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Procedure Type21.9%
Indication23.4%
Embolic Agent13.0%
End User20.9%
Product Type20.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.8
- Europe21.5
- Asia Pacific23.0
- Latin America13.9
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Boston Scientific Corporation | 90 | 76 | 83 | 79 | 84 | 93 | 84 |
| Terumo Corporation | 74 | 77 | 90 | 69 | 72 | 83 | 78 |
| Cook Medical (a division of Cook Group) | 73 | 83 | 68 | 74 | 87 | 64 | 75 |
| Medtronic plc | 71 | 80 | 82 | 81 | 70 | 66 | 75 |
| Becton | 62 | 60 | 63 | 77 | 54 | 56 | 62 |
| Dickinson and Company (BD) | 67 | 59 | 58 | 58 | 67 | 52 | 60 |
| Siemens Healthineers | 44 | 48 | 63 | 47 | 50 | 58 | 52 |
| Philips Healthcare | 44 | 55 | 35 | 44 | 40 | 47 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Boston Scientific Corporation
- Terumo Corporation
- Cook Medical (a division of Cook Group)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Boston Scientific Corporation | ✓ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Terumo Corporation | ◐ | ◐ | ✓ | ◐ | − | ✓ |
| Cook Medical (a division of Cook Group) | ◐ | ✓ | ◐ | ◐ | ✓ | − |
| Medtronic plc | ✓ | ◐ | ◐ | ◐ | ◐ | ✓ |
| Becton | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Dickinson and Company (BD) | ◐ | − | − | − | ◐ | ◐ |
| Siemens Healthineers | − | − | ◐ | − | − | ◐ |
| Philips Healthcare | − | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Boston Scientific Corporation84
2Terumo Corporation78
3Cook Medical (a division of Cook Group)75
4Medtronic plc75
5Becton62
6Dickinson and Company (BD)60
7Siemens Healthineers52
8Philips Healthcare44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Boston Scientific CorporationTerumo Corporation
Challenger2
Strong scale, closing on the leaders.
Cook Medical (a division of Cook Group)Medtronic plc
Contender2
Focused players with pockets of strength.
BectonDickinson and Company (BD)
Niche2
Specialists in a single segment or region.
Siemens HealthineersPhilips Healthcare
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Procedure Type in North America, then scale across Transarterial Chemoembolization (TACE) Market — a $414M beachhead inside a $6.51B market.
Beachhead (SOM)$414Mobtainable near-term
Serviceable (SAM)$2.60Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Conventional TACE (cTACE)
Best fit — highest urgency & budget in Procedure Type.
Economic buyer78 fit
Drug-Eluting Beads TACE (DEB-TACE)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Balloon-Occluded TACE (B-TACE)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Procedure Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Indication & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Embolic Agent
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel27%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Procedure Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Transarterial Chemoembolization (TACE) Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation14%
Closed-won6%
$11.8KCAC
$69KLTV
5.8:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Transarterial Chemoembolization (TACE) Market is a high-growth opportunity — $5.42B by 2033, compounding at 11.3%.
TAM · 2025$2.31Btoday
TAM · 2033$5.42Bforecast
CAGR11.3%2027–2033
Cumulative$33.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.42BTotal addressable market
SAM$1.97BServiceable available market
SOM$418MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.3% CAGR
Demand compounds through 2033, outpacing GDP across Procedure Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Procedure Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.42BLarge & growingTAM by 2033 at 11.3% CAGR
$1.97BServiceable nowreachable with today’s model
$418MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.22BBear7.3% CAGR
$5.42BBase11.3% CAGR
$6.93BBull14.9% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Indication optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Transarterial Chemoembolization (TACE) Market — a $4.45B market by 2033. Plan: grow share from 7.9% to 13.1%.
Market size · 2033$4.45Btotal addressable
Market CAGR4.6%2027–2033
Target share13.1%from 7.9% today
Revenue ambition$583Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.9% | 13.1% | Behind |
| Revenue | $382M | $583M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 30.8% | 42.9% | On track |
| Customer retention | 86.1% | 95.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Procedure Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Indication capability
A defensible second engine — invest in Indication to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Procedure Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Indication
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $64M capacity & capability investment
- Greenlight bolt-on M&A in Indication
- Authorise North America expansion plan
- Fund R&D program for Procedure Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskAhead
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Transarterial Chemoembolization (TACE) Market conversation — a $8.40B market you can size, segment and defend in minutes.
Market size · 2033$8.40Btotal opportunity
Growth8.9%CAGR to 2033
Addressable buyers1,526+accounts in scope
Typical ROI6.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Procedure Type
Goal Grow share in Procedure Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.6×return on cost, year one
< 4 mopayback period
$69K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Boston Scientific CorporationTerumo CorporationCook Medical (a division of Cook Group)Medtronic plcBectonDickinson and Company (BD)Siemens HealthineersPhilips Healthcare+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Transarterial Chemoembolization (TACE) Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Transarterial Chemoembolization (TACE) Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Transanal Irrigation in Children Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportTranexamic Acid Toothpaste Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportTranexamic Acid Injection Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportTranexamic Acid API Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportTrametinib Market
Market size, share, segmentation and regional forecast.
$392M market · 2025 base year
View reportTramadol (INN) Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportTraining Manikins Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportTraining External Defibrillators Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportTRAIL Antibody Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportTRAF2 Antibody Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportTraditional Wound Dressing Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportTraditional Wound Care Products Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.